thalidomide has been researched along with Cancer of Spleen in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate thalidomide as an adjuvant treatment for canine haemangiosarcoma." | 7.88 | Does thalidomide prolong survival in dogs with splenic haemangiosarcoma? ( Bray, JP; Cave, N; Munday, JS; Orbell, G, 2018) |
| "To investigate thalidomide as an adjuvant treatment for canine haemangiosarcoma." | 3.88 | Does thalidomide prolong survival in dogs with splenic haemangiosarcoma? ( Bray, JP; Cave, N; Munday, JS; Orbell, G, 2018) |
| " Although treatment was initiated with thalidomide, the patient developed multiple organ dysfunction syndrome (MODS) and succumbed to his disease." | 3.73 | Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon. ( Bölke, E; Budach, W; Gripp, S; Orth, K; Peiper, M; Reinecke, P; Schwarz, A; van de Nes, JA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bray, JP | 1 |
| Orbell, G | 1 |
| Cave, N | 1 |
| Munday, JS | 1 |
| Thieblemont, C | 1 |
| Haidar, JH | 1 |
| Bazarbachi, A | 1 |
| Nasr, MR | 1 |
| El-Sabban, ME | 1 |
| Daher, R | 1 |
| Bölke, E | 1 |
| Gripp, S | 1 |
| Peiper, M | 1 |
| Budach, W | 1 |
| Schwarz, A | 1 |
| Orth, K | 1 |
| Reinecke, P | 1 |
| van de Nes, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
1 review available for thalidomide and Cancer of Spleen
| Article | Year |
|---|---|
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide | 2017 |
3 other studies available for thalidomide and Cancer of Spleen
| Article | Year |
|---|---|
Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?
Topics: Angiogenesis Inhibitors; Animals; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Female; Hemangiosarcom | 2018 |
Signet ring-like light chain myeloma with systemic spread.
Topics: Anemia; Antineoplastic Agents; Bone Marrow Examination; Combined Modality Therapy; Diagnostic Errors | 2003 |
Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Fatal Outcome; Hemangioendothelioma, Epithelioid; | 2006 |